Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2017 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (215)	6/25/2017 8:10:06 AM
From: Howard Williams	1 Recommendation Recommended By Thehammer Read Replies (1) \| Respond to of 344

Greetings Bulba. OMER is also MY largest stock position, by a significant margin even before the recent run-up. I've been in it since just after the IPO which I (luckily) was unable to get into, and have accumulated my position at favorable prices ......... even trading 10% or so actively, taking advantage of OMER's odd daily .... sometimes hourly ..... gyrations. Good luck to all OMER longs! ........... OMS721 is the key ......

To: BulbaMan who wrote (215)	6/30/2017 11:52:30 PM
From: BulbaMan	Read Replies (1) \| Respond to of 344

6/30/2017 Contest update As the POTUS might put it, biotechs had a facelift this week and the bleeding was ugly. But, despite the sanguineous week, biotechs wound up with nice gains for both June and for the second quarter. At the close of Q2, the Nasdaq Biotech Index (NBI) was up 17.06% compared to up 10.70% at the close of Q1, while the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI) was up 30.58%, at the close of Q2 compared to 17.29% at the close of Q1. As for the Contest median, it also had a positive second quarter although not matching the Indexes. It extended its gain to 20.00% at the close of Q2 from 17.39% at the close of Q1. I will post additional second quarter performance data for Contest portfolios and Contest stock picks shortly. Meanwhile, at Friday’s close, as noted above the Contest median was up 20.00% YTD (vs. up 25.61% YTD a week ago), the Nasdaq Biotech Index (NBI) was up 17.06% YTD (vs. up 20.97% YTD a week ago) and the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI) was up 30.58% YTD (vs. up 36.03% YTD a week ago). The Nasdaq Composite Index (NCI) closed up 14.07% YTD (vs. up 16.39% YTD a week ago). BIOADD’s portfolio, with help from SBBP, jumped from fourth place last Friday into the Contest lead and is now up 66.45% YTD. HRS’s portfolio, up 61.16% YTD, remained in second place and ROBO’s portfolio, up 61.10% YTD, was a smidgen below in third place. At Friday's close, 44 of the 48 Contest portfolios were still in the green, with 29 beating the NBI and 13 beating the SPSIBI. The 195 Contest portfolio stock picks have an average YTD gain of 18.40% and a median YTD gain of 10.38%, with 115 of the 195 picks up for the year. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the week ranked by % Gained and % Lost YTD. (Prices not converted to US$ in these Tables.) Portfolio adjustments: None (All corrections, especially adjustments for splits, greatly appreciated.) Enjoy a safe and fun Independence Day biotechies! Peace & good health, Bulba 6/30/17 Rank Name Profit/Loss 1 BIOADD 66,449 2 HRS 61,155 3 ROBO 61,097 4 SMALLB 49,748 5 TOMP 49,407 6 YVR 48,235 7 KMASTR 45,978 8 TUCK 42,425 9 BIOMAV 39,707 10 RKRW 39,402 Week's Top 5 Gainers Symbol 6/23/17 6/30/17 Wk.%chg. ORPN 0.43 0.67 54.73% IPIX 0.72 0.96 34.25% CAPR 0.63 0.83 30.91% SBBP 5.50 7.15 30.00% ADMA 3.15 3.84 21.90% Week's Worst 5 Losers Symbol 6/23/17 6/30/17 Wk.%chg. ALDR 19.70 11.45 -41.88% CARA 22.65 15.39 -32.05% XENE 4.100 3.150 -23.17% OMER 25.71 19.91 -22.58% GLYC 13.41 11.16 -16.78%